Last reviewed · How we verify
NCT04287894: Induction
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
Phase 1 trial testing Durvalumab in Stage III NSCLC in 18 participants. Terminated before completion.
4 November 2024
Quick facts
| Lead sponsor | The Netherlands Cancer Institute |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 28 December 2018 |
| Primary completion | 4 November 2024 |
| Estimated completion | 4 November 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Durvalumab — full drug profile →
- Tremelimumab (TREMELIMUMAB) — full drug profile →
- Pemetrexed — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
- chemo radiotherapy
- Resection
Conditions studied
- Stage III NSCLC — all drugs for Stage III NSCLC →
Sponsor
The Netherlands Cancer Institute
Who can join
18 and older, any sex, with Stage III NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists.
Glatzer M, Leskow P, Caparrotti F, Elicin O, et al · · 2021 · cited 22× · PMID 34012806 · DOI 10.21037/tlcr-20-1210 -
New developments in locally advanced nonsmall cell lung cancer.
Huber RM, Kauffmann-Guerrero D, Hoffmann H, Flentje M. · · 2021 · cited 12× · PMID 33952600 · DOI 10.1183/16000617.0227-2020 -
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.
Peng Y, Li Z, Fu Y, Pan Y, et al · · 2023 · cited 11× · PMID 36761954 · DOI 10.3389/fonc.2023.1011810 -
Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer.
Allaeys T, Berzenji L, Lauwers P, Yogeswaran SK, et al · · 2022 · cited 7× · PMID 35406428 · DOI 10.3390/cancers14071656 -
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.
Burcher K, Karukonda P, Kelsey C, Mullikin T, et al · · 2025 · cited 3× · PMID 40507315 · DOI 10.3390/cancers17111829 -
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial.
Smeenk MM, van Diessen JNA, Boellaard TN, Hartemink KJ, et al · · 2025 · cited 2× · PMID 39821070 · DOI 10.1158/1078-0432.ccr-24-3476
Verify or expand the search:
- PubMed search for NCT04287894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Durvalumab
Trials testing the same drug.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
Other recruiting trials for Stage III NSCLC
Currently open trials in the same condition.
- NCT07264647 — Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
- NCT05740943 — Induction Lorlatinib in Stage III Non-small Cell Lung Cancer · Phase 2 · active not recruiting
Other The Netherlands Cancer Institute trials
Trials by the same sponsor.
- NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
- NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
- NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
- NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
- NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04287894 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
- Last refreshed: 6 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04287894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing